We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
American Peptide Company Adds Research and Development Group to Enhance Technology Capabilities
News

American Peptide Company Adds Research and Development Group to Enhance Technology Capabilities

American Peptide Company Adds Research and Development Group to Enhance Technology Capabilities
News

American Peptide Company Adds Research and Development Group to Enhance Technology Capabilities

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "American Peptide Company Adds Research and Development Group to Enhance Technology Capabilities"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

American Peptide Company has announced the formation of a new research and development group. Created to offer technology capabilities to a growing roster of global pharmaceutical and biotech customers, the R&D group will be based at the company’s Sunnyvale, California facility and will be tasked with the development of new products and services.

Peptide drugs are increasing in complexity, now requiring challenging modifications, incorporating unnatural amino acids, and being linked to carrier molecules to enhance drug delivery efficacy.

Designed for indications to treat ailments such as diabetes, HIV, neurological disorders like Alzheimer’s disease, cardiovascular diseases, and cancer, peptides have tremendous therapeutic potential, but can be difficult to synthesize to the high quality necessary for research and commercial production. American Peptide Company has instituted the R&D group to help meet this industry need and provide peptide solutions to the drug development community.

“The new R&D group will better enable American Peptide Company to meet the complex and evolving needs of our global customer base,” says Takahiro Ogata, President & COO of American Peptide Company. “This initiative fits well with our broader company mission to provide Total Peptide Management solutions to drug researchers and developers pioneering solutions for improving human life. The R&D group and the technological capabilities they offer will ultimately help our customers more effectively drive bioactive peptides identified as potential drug targets through the discovery and development phase.”
Advertisement